直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Securing $240 million and a jury verdict of willful infringement for Promptu in patent case against Comcast

Promptu Systems Corporation

US Synthetic secures ITC exclusion order barring polycrystalline diamond compacts (PDCs)

US Synthetic Corporation

Achieving precedent in preserving valuable patents for Lumify®

Eye Therapies, LLC

Finnegan client Maglula delivers crushing blow to Amazon’s arbitration practices over counterfeit products

Maglula, Ltd.

Finnegan secures $180M for CSRC in complex arbitrations

CSRC et al.

Protecting a blockbuster diabetes treatment for AstraZeneca

AstraZeneca AB

Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini

Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement

Eisai Co., Ltd.

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Recent Experience

Experience

In re Lumify

In re Lumify

3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock

Experience

Merck Sharp & Dohme LLC v. Hetero USA Inc., Lupin Limited et al. Merck Sharp & Dohme LLC v. Hetero USA Inc., Lupin Limited et al.

2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre

Experience

Representative Engagement: Protecting a blockbuster diabetes treatment for AstraZeneca - AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc., 1:18-cv-00664, D. Del.

Protecting a blockbuster diabetes treatment for AstraZeneca Protecting a blockbuster diabetes treatment for AstraZeneca

1:18-cv-00664, D. Del., Judge Andrews

Experience

Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc. Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc.

1:21-cv-01015, D. Del., Judges Hall, Williams

Experience

KeyMe, LLC v. The Hillman Group, Inc. KeyMe, LLC v. The Hillman Group, Inc.

1:19-cv-01539, D. Del., Judge Stark

Experience

The Hillman Group, Inc. v. KeyMe, LLC The Hillman Group, Inc. v. KeyMe, LLC

2:19-cv-00209; 2:20-cv-00070, E.D. Tex., Judge Gilstrap

Experience

Shire ViroPharma Inc. v. CSL Behring LLC Shire ViroPharma Inc. v. CSL Behring LLC

1:17-cv-00414, D. Del., Judges Goldberg, Thynge

Experience

AbbVie Biotechnology; Abbott GmbH Ltd. v. InterLab Limited; Merck-Serono Limited AbbVie Biotechnology; Abbott GmbH Ltd. v. InterLab Limited; Merck-Serono Limited

WIPOA120712, WIPO

Experience

The Hillman Group, Inc. v. Minute Key, Inc.  The Hillman Group, Inc. v. Minute Key, Inc. 

1:13-cv-00707, S.D. Ohio, Judge Dlott

Experience

AstraZeneca LP v. SigmaPharm Laboratories AstraZeneca LP v. SigmaPharm Laboratories

1:15-cv-01000, D. Del., Judge Andrews

Experience

Velocys, Inc. et al. v. Catacel Corp.  Velocys, Inc. et al. v. Catacel Corp. 

5:10-cv-00747, N.D. Ohio, Judge Adams

Experience

In re Osslund  In re Osslund 

2013-004840, PTAB, Judges Green, Guest, Lebovitz
Reexamination Control 95/000,440, PTAB

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP